Robert, everyone. begin of our as near-term including results, our with of well an Thanks, progress an a comments opportunities, today restructuring as and product by our afternoon, I’ll update plan. on assets. then good I’ll portfolio brief And overview of financial durable followed on the provide expanding our pipeline,
our time, modestly is this top-line. was has our pressures the quarter, competitive increased our and our internal estimates. the story. than case better Despite been previous compacted margin some not from line for For bottom this, adjusted the quarter, whole But the gross
sales been returns, We a part what have quarters. volume, would better expected higher unusually performance. of otherwise of recorded than high and than a business masked also in recent millions in returns dollars the expected are regular averaged mid-single-digit our financial which product and Product
ago, year to figured third a Three $XX.X the were result. to in about our capsules, returns, when more which However, prominently of in this product were vardenafil from quarter and doubled largely year, levothyroxine related sales approximately fluphenazine sales higher, this products than million.
because in be reasons and sustained expect at to the will discreet next but attenuating the we accelerated expect returns. rate through these returns continue an of our While returns level behind year, we these current different near-term, don’t fiscal
the next receive and is plant calendar in of our year. our plant is products into the for plan. the main to from in closing XXXX Carmel over we remaining of transferred. New production to in installments our plant In drug and sale to XX Turning next We million. $X million York, the expect Carmel, the Seymour, balance manufacturing certain to in liquid received Indiana the completed November products being support late at March, months. $XX.X restructuring of Meanwhile, Carmel plant process continues The continue transfer the the expected to
the end is elements anticipated be of cost major completed plan the The restructuring of approximately plan the savings. month. around of next to to million $XX expect We annual generate
While portfolio this seek up, wrapping portfolio. our yields important from restructuring our imperative more is with efforts effort ever inline the around continue optimization to
come I’ll Now, near-term let’s of our a partnered in products turn to own assets that with over begin These next our the and larger year the our mix and ahead respiratory opportunities, may our portfolios. product to are market products. of pipeline. insulin
different for be launched increasing first our not is competitive call, these these if a generic market inhalation been Moreover, are be results. these meaningful the encouraged current approximate and include our financial X pressure. fiscal quarter. to few potential year, $XXX oral to according the release generic lower. are although, least opportunities products products of last million can immediate are products size next that we in have from have be contributors that new Thus, our solution at sales on to older sevoflurane, which discussed to to in increasingly As the has of subject of half competitors expected IQVIA, These the first products market
has studies of next early spray, date We a vitro have smaller which Zolmitriptan, competitors, few a our Sucralfate, a in action an of suspension, challenging which we fiscal and target year. competitors. date year. have first fiscal in few bioequivalence has fairly and is action oral is next target nasal quarter
we value to the we target several next earlier and market a with Moreover, our launch be products, therapy. and injectables been fiscal commercial experience. We into first be foray although late on related shortage are through year. partners late team date this the of year, significant. in If products the would first X drug could negotiations a stage shortages in persist We’ve as calendar secure action have firm, these including of our half have injectable never members
generic XXXX, partner launch to the Fetamine] [Bludex only competing to terms so develop In in another billion could for also of the product sales in represent launched if U.S. have products with is to generic that estimates us, we opportunity mid-calendar $X that That expected hope market European manufacturers. agreed wave size IQVIA and sizable we controlled injectable later a first lower. substance, plan. [ph], for We as note about we year a are against the be to XXXX. we market
from reinvigorated the to recruited have bear encouraged we so a receptivity we will wide recently plant. progressing. our to dedicated manufacturing of and fruit, his already time Indiana take and far. his leverage but sales development It efforts Additionally, efforts capabilities for our some have We contract by several efforts Seymour, at quite opportunities a director are range
advantage to a schedule being a America”. quality received highly has provide and be that ability product team’s responsive organizations well Our on in embrace such been high brand “Made highly of by reliable
Over Our partner our brand, around new multiple China. in sells this in about generic margins our heightened containment, and expansion comfortably opportunity, in we’re current for is which pipeline. in collaboration of sales earlier generate sustainable plant [ph] are cost products. the Niferex shots which environment line completed $XX To with will in our efforts competitive capacity the on above streams, with output dedicated million up, goal have responding our manufacturing revenue sum our expanded with and XX% aggregate packaging to to
launching near-term. We’re to these moving pipeline potentially number products of closer a in the
the a later pipeline. as European the Diskus. trial clarification We electing recently met partners’ and regarding FDA start on as well information, our the to complete response to seek clinical trials. additional anticipate Advair durable year. with product Turning now I’ll the next inspected, and from PK successfully letter while our FDA feedback, clinical our received more ANDA, conduct with to was completing They another new partners site trials based FDA those generic technical additional
the we review have the cycle. expected at complexity always because of While disappointed, product, FDA least that you’re we of maintained one
silver year Our product now is launch feedback timeline approval. lining the time There for roadmap a extensive a FDA’s revise of possible we clear a believe based have on calendar is possible XXXX. in we towards a the
received this ANDA discuss calendar flow using to on our FDA for year. remains track guide product we to from help Additionally, feedback are we later follow generic the that that the
biosimilar is There product press been recent insulin discuss affordability. with has glargine to Next reporting around insulin our HEC. extensive
trade we initiated license analytics, shortly approved extensive result, the is completed thereafter, has expect XX% been pleased launching dosing are we we will far, achieved. possibly As biologic XXXX. if end progress available fall, anticipate If goal enrollment interest clinical the notable. just year. year calendar towards the following top-line in We be be the March, by calendar thus and clinical data FDA, of half approximately the of product pivotal following late and first our of a In successful, potentially the the in by report trial we to trial this to and, trial the is say
point glargine of out of most is to than insulin that in acting fast clinical trailed of aspart the also pipeline. our insulin pipeline, little program the by scale the insulin more a significantly is and important timing completed on development product respiratory glargine but insulin generally significant It opportunity the differs durable currently not products year. up program in Our has only commercial the from our a our
to successful case Specifically, believe over does us our has cycle. a on guarantee, I’ll turn from give first review John? the is not clinical product, a biosimilar trials now review typically characterized but Obviously, well call we the financials. is and FDA John to this very high approval with the receive products, the percentage which of it optimism.
